No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomi
Huang YQ, Tang SQ, Xu XL, Zeng YM, He XQ, Li Y, Harypursat V, Lu YQ, Wan Y, Zhang L, Sun QZ, Sun NN, Wang GX, Yang ZP, Chen YK.
Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
Fintelman-Rodrigues N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, Ferreira AC, Mattos M, de Freitas CS, Cardoso Soares V, da Silva Gomes Dias S, Temerozo JR, Miranda MD, Matos AR, Bozza FA, Carels N, Alves CR, Siqueira MM, Bozza PT, Souza TML.
Breast surgeons updating on the thresholds of COVID-19 era: results of a multicenter collaborative study evaluating the role of online videos and multimedia sources on breast surgeons education and training
Marcasciano M, Kaciulyte J, Mori FLR, Lo Torto F, Barellini L, Loreti A, Fanelli B, De Vita R, Redi U, Marcasciano F, Di Cesare F, Dal Pr√† G, Conversi A, Elia L, Montemari G, Vaia N, Bernini M, Sordi S, Luridiana G, D'Ermo G, Monti M, De Luca A, Ricci F, Mazzocchi M, Gentilucci M, Greco M, Losco L, Valdatta LA, Raposio E, Giudice G, Maruccia M, Di Benedetto G, Cigna E, Casella D, Ribuffo D.
Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19
Lofgren SMM, Nicol MR, Bangdiwala AS, Pastick KA, Okafor EC, Skipper CP, Pullen MF, Engen NW, Abassi M, Williams DA, Nascene AA, Axelrod ML, Lother SA, MacKenzie LJ, Drobot G, Marten N, Cheng MP, Zarychanshi R, Schwartz IS, Silverman M, Chagla Z, Kelley LE, McDonald EG, Lee TC, Hullsiek KH, Boulware DR, Rajasingham R.
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial
Nanni O, Viale P, Vertogen B, Lilli C, Zingaretti C, Donati C, Masini C, Monti M, Serra P, Vespignani R, Grossi V, Biggeri A, Scarpi E, Galardi F, Bertoni L, Colamartini A, Falcini F, Altini M, Massa I, Gaggeri R, Martinelli G.
Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Humphrey LL.
Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial
Grau-Pujol B, Camprub√≠ D, Marti-Soler H, Fern√°ndez-Pardos M, Guinovart C, Mu√±oz J.
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking
Silva Arouche TD, Reis AF, Martins AY, S Costa JF, Carvalho Junior RN, J C Neto AM.
Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care
Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM, Soriano Viladomiu A, Robinson P, Gottlieb RL, Tsang TYO, Lee IH, Haubrich RH, Chokkalingam AP, Lin L, Zhong L, Bekele BN, Mera-Giler R, Gallant J, Smith LE, Osinusi AO, Brainard DM, Hu H, Phulpin C, Edgar H, Diaz-Cuervo H, Bernardino JI.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W.
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, Naninck T, Pizzorno A, Lemaitre J, Gon√ßalves A, Kahlaoui N, Terrier O, Fang RHT, Enouf V, Dereuddre-Bosquet N, Brisebarre A, Touret F, Chapon C, Hoen B, Lina B, Calatrava MR, van der Werf S, de Lamballerie X, Le Grand R.
Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19
Response to: "Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients" and "Re: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis"
Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ.
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial
Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, Nascene AA, Hullsiek KH, Cheng MP, Luke D, Lother SA, MacKenzie LJ, Drobot G, Kelly LE, Schwartz IS, Zarychanski R, McDonald EG, Lee TC, Rajasingham R, Boulware DR.
Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study
Fern√°ndez-Ruiz M, L√≥pez-Medrano F, As√≠n MAP, de la Calle GM, Bueno H, Caro-Teller JM, Catal√°n M, de la Calle C, Garc√≠a-Garc√≠a R, G√≥mez C, Laguna-Goya R, Lizaso√°in M, Mart√≠nez-L√≥pez J, Orig√ºen J, Pablos JL, Ripoll M, Juan RS, Trujillo H, Lumbreras C, Aguado JM; H12O Immunomodulation Therapy for COVID-19 Group.
Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs
Duran-Frigola M, Bertoni M, Blanco R, Mart√≠nez V, Pauls E, Alcalde V, Turon G, Villegas N, Fern√°ndez-Torras A, Pons C, Mateo L, Guitart-Pla O, Badia-I-Mompel P, Gimeno A, Soler N, Brun-Heath I, Zaragoza H, Aloy P.
The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial
Denholm JT, Davis J, Paterson D, Roberts J, Morpeth S, Snelling T, Zentner D, Rees M, O'Sullivan M, Price D, Bowen A, Tong SYC; ASCOT Investigator Group.
Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada
Wright JK, Tan DHS, Walmsley SL, Hulme J, O'Connor E, Snider C, Cheng I, Chan AK, Borgundvaag B, McLeod S, Gollob MH, Clarke RJ, Dresser L, Haji F, Mazzulli T, Mubareka S, J√ºni P, Lee D, Tomlinson G, Kain KC, Landes M.
Correction to: ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial
McEniery CM, Fisk M, Miles K, Kaloyirou F, Hubsch A, Smith J, Wilkinson IB, Cheriyan J.
Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to, 'COVID-19: Immunology and treatment options', Felsenstein, Herbert McNamara et al. 2020'
McIlroy JR, Mullish BH, Goldenberg SD, Ianiro G, Marchesi JR.
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a stu
Smith K, Pace A, Ortiz S, Kazani S, Rottinghaus S.
Reply to letters vide manuscript ID IPEJ-D-20-00072, and IPEJ-D-20-00073 regarding our paper "Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm SocietyÀÆ
Kapoor A, Pandurangi U, Arora V, Gupta A, Jaswal A, Nabar A, Naik A, Naik N, Namboodiri Kk N, Vora A, Yadav R, Saxena A.
SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS
Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, Fumagalli R, Bottiroli M, Mondino M, Merli M, Bellone A, Basile A, Ruggeri R, Colombo F, Moreno M, Pastori S, Perno CF, Tarsia P, Epis OM, Puoti M; Niguarda COVID-19 Working Group.
Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial
Response to: 'Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?' by Santos-Mareno et al
Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial
Saiz-Rodr√≠guez M, Pe√±a T, L√°zaro L, Gonz√°lez √Å, Mart√≠nez A, Cordero JA, Vicente JT, Richard F, Coma MJ, de Frutos M, Labrador J, Pueyo A.
The course of Covid 19 in Inflammatory Bowel Disease: protective role of TNF antagonists Response to: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
Marzolini C, Stader F, Stoeckle M, Franzeck F, Egli A, Bassetti S, Hollinger A, Osthoff M, Weisser M, Gebhard CE, Baettig V, Geenen J, Khanna N, Tschudin-Sutter S, Mueller D, Hirsch HH, Battegay M, Sendi P.
Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU
Du≈°ka F, Waldauf P, Halaƒçov√° M, Zvon√≠ƒçek V, Bala J, Bal√≠k M, Bene≈° J, Klementov√° O, Koz√°kov√° I, Kubricht V, Le Roy A, Vymazal T, ≈òeho≈ôov√° V, ƒåern√Ω V; Czech Anaesthesia Clinical Trials and Audit Network.
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial
Kulkarni S, Fisk M, Kostapanos M, Banham-Hall E, Bond S, Hernan-Sancho E, Norton S, Cheriyan J, Cope A, Galloway J, Hall F, Jayne D, Wilkinson IB.
Rapid and sensitive diagnostic procedure for multiple detection of pandemic Coronaviridae family members SARS-CoV-2, SARS-CoV, MERS-CoV and HCoV: a translational research and cooperation between the Phan Chau Trinh University in Vietnam and University of Bari "Aldo Moro" in Italy
Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy
Cavagna L, Seminari E, Zanframundo G, Gregorini M, Di Matteo A, Rampino T, Montecucco C, Pelenghi S, Cattadori B, Pattonieri EF, Vitulo P, Bertani A, Sambataro G, Vancheri C, Biglia A, Bozzalla-Cassione E, Bonetto V, Monti MC, Ticozzelli E, Turco A, Oggionni T, Corsico A, Bertuccio F, Zuccaro V, Codullo V, Morosini M, Marena C, Gnecchi M, Pellegrini C, Meloni F.
No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France"
The peripheral lymphocyte count as a predictor of severe COVID-19 and the effect of treatment with ciclesonide
Yamasaki Y, Ooka S, Tsuchida T, Nakamura Y, Hagiwara Y, Naitou Y, Ishibashi Y, Ikeda H, Sakurada T, Handa H, Nishine H, Takita M, Morikawa D, Yoshida H, Fujii S, Morisawa K, Takemura H, Fujitani S, Kunishima H.
The Risk of Respiratory Tract Infections in Psoriasis Patients Treated With IL-23-pathway Inhibiting Biologics: A Meta-Estimate of Pivotal Trials Relevant to Decision-Making During the COVID-19 Pandemic
Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM.
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Querini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo A, De Cobelli F, Dagna L; SARI-RAF Study Group; SARI-RAF Study Group members.
Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Pl√º√ü et al
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial
McEniery CM, Fisk M, Miles K, Kaloyirou F, Vamvaka E, Hubsch A, Smith J, Wilkinson IB, Cheriyan J.
Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial
Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods
Albahri OS, Al-Obaidi JR, Zaidan AA, Albahri AS, Zaidan BB, Salih MM, Qays A, Dawood KA, Mohammed RT, Abdulkareem KH, Aleesa AM, Alamoodi AH, Chyad MA, Zulkifli CZ.
Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, Lei F, Chen MM, Yang H, Bai L, Song X, Lin L, Xia M, Zhou F, Zhou J, She ZG, Zhu L, Ma X, Xu Q, Ye P, Chen G, Liu L, Mao W, Yan Y, Xiao B, Lu Z, Peng G, Liu M, Yang J, Yang L, Zhang C, Lu H, Xia X, Wang D, Liao X, Wei X, Zhang BH, Zhang X, Yang J, Zhao GN, Zhang P, Liu PP, Loomba R, Ji YX, Xia J, Wang Y, Cai J, Guo J, Li H.
Clinical course and outcome of COVID-19 in patients with rheumatic diseases: are all biological disease-modifying antirheumatic drugs alike? Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al
Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics
Mendel A, Bernatsky S, Askanase A, Bae SC, Clarke AE, Costedoat-Chalumeau N, Gladman DD, Gordon C, Hanly J, Jacobsen S, Kalunian K, Mak A, Mosca M, Pons-Estel BA, Ruiz-Irastorza G, Urowitz M, Vinet √â.
A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore¬Æ-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial"
Tornero C, Vallejo R, Cede√±o D, Ordu√±a J, Pastor E, Belaouchi M, Escamilla B, Laredo M, Del Mar Garzando M.
Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol
Marietta M, Vandelli P, Mighali P, Vicini R, Coluccio V, D'Amico R; COVID-19 HD Study Group.
Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial
Allahyari A, Rahimi H, Khadem-Rezaiyan M, Mozaheb Z, Seddigh-Shamsi M, Bary A, Kamandi M, Azimi SA, HasanAbadi SE, Noferesti A, Shariatmaghani SS, Rafatpanah H, Khatami S, Imani AJ, Mortazi H, Nodeh MM.
Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases
Tsuchiya A, Takeuchi S, Iwasawa T, Kumagai M, Sato T, Motegi S, Ishii Y, Koseki Y, Tomiyoshi K, Natsui K, Takeda N, Yoshida Y, Yamazaki F, Kojima Y, Watanabe Y, Kimura N, Tominaga K, Kamimura H, Takamura M, Terai S.
Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic et al
Schulze-Koops H, Krueger K, Specker C; Kommission Pharmakotherapie of the German Society of Rheumatology.
A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on https://doi.